Abstract

[...]not all patients can benefit from this combination treatment. [...]identifying biomarkers of response before treatment initiation is urgently needed. Tumor samples from biopsy are hardly available from advanced HCC patients. [...]exploring biomarkers from peripheral blood seems more rational. [...]patients with SD were added to the validation cohort to perform a sensitivity analysis (Figure 1A). [...]peripheral naïve CD8+ T cells could

Details

Title
Peripheral naïve CD8+ T cells as a predictive biomarker of response to lenvatinib plus an anti‐PD‐1 antibody in advanced hepatocellular carcinoma: a biomarker study
Author
Huang, Cheng 1 ; Xu, Bin 1   VIAFID ORCID Logo  ; Xiao‐Dong Zhu 1 ; Ying‐Hao Shen 1 ; Mei‐Ling Li 1 ; Jin‐Jin Zhu 1 ; Zhou, Jian 1 ; Fan, Jia 1 ; Hui‐Chuan Sun 1 

1  Department of Liver Surgery and Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, P. R. China 
Pages
1226-1230
Section
LETTERS TO THE EDITOR
Publication year
2022
Publication date
Nov 2022
Publisher
John Wiley & Sons, Inc.
e-ISSN
2523-3548
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1002/cac2.12350
ProQuest document ID
2734592775
Copyright
© 2022. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.